Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9516
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNayler, W Gen
dc.date.accessioned2015-05-15T22:38:19Z
dc.date.available2015-05-15T22:38:19Z
dc.date.issued1992-12-01en
dc.identifier.citationJournal of Human Hypertension; 6 Suppl 1(): S19-23en
dc.identifier.govdoc1284082en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9516en
dc.description.abstractAtherosclerosis is a complex and multifactorial disease, the endpoint of which is the formation of a calcified plaque. Intermediate events include intimal injury, smooth muscle cell proliferation and migration, macrophage infiltration, lipid accumulation and excess formation of ground substance. To determine whether the newly developed, long-acting calcium antagonist, amlodipine, slows the development of atherosclerotic lesions under experimental conditions, young New Zealand white rabbits were fed on a diet of 2% cholesterol plus 1% peanut oil for up to 12 weeks. Half the rabbits received 1 or 5 mg amlodipine/kg body weight/day. Amlodipine caused a significant and dose-dependent reduction in lesion formation in the thoracic aorta. At the same time thoracic aorta Ca2+ and cholesterol content were maintained at near normal levels, despite the raised plasma cholesterol levels. The protective effect of amlodipine persisted throughout a treatment period of 12 weeks, indicating the absence of tachyphylaxis.en
dc.language.isoenen
dc.subject.otherAmlodipine.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherAorta.chemistry.pathologyen
dc.subject.otherArteriosclerosis.metabolism.prevention & controlen
dc.subject.otherCalcium.analysis.metabolismen
dc.subject.otherCholesterol.analysis.blood.metabolismen
dc.subject.otherDose-Response Relationship, Drugen
dc.subject.otherMaleen
dc.subject.otherRabbitsen
dc.subject.otherStaining and Labelingen
dc.subject.otherTime Factorsen
dc.titleThe antiatherogenic effects of amlodipine: promise of preclinical data.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of human hypertensionen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pagesS19-23en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1284082en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.